drugset / Trial / NCT01642342
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
Phase 1
Terminated
102 enrolled
University of Southern California
National Cancer Institute (NCI) · collabThe V Foundation for Cancer Research · collabVasgene Therapeutics, Inc · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study is about an experimental drug called sEphB4-HSA (recombinant albumin fusion protein sEphB4-HSA). This research study will be the first time sEphB4-HSA is given to people. sEphB4-HSA prevents tumor cells from multiplying and blocks several compounds that promote the growth of blood vessels that bring nutrients to the tumor. sEphB4-HSA has shrunk colon, lung, breast, glioma, melanoma, prostate and Kaposi's sarcoma tumors in mice
Timeline
- Start
- 2012-09-06
- Primary completion
- 2019-05-29
- Completion
- 2019-05-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | sEphB4-HSA | Protein / enzyme biologic | — | Intravenous |